

RECOMMENDATIONS

- Studying other genes responsible for HCV related MC and another site of polymorphism in BAFF promoter gene rather than-871C/T.
- Conducting further studies on a larger population regarding the protective role of BAFF polymorphism.
- Conducting the study using real time PCR technique, this could give more accurate and reliable results.
- Conducting further studies on the safety and benefit of including anti BAFF antibody supplements in treatment protocols of HCV related MC.

REFERENCES

1. Stübgen JP. Neuromuscular diseases associated with chronic hepatitis C virus infection. *J ClinNeuromuscul Dis* 2011;13(1):14-25.
2. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. *J ClinPharmacol* 2004; 44(1):20-9.
3. Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Epidemiology, Transmission and Natural History. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editor. Short guide to hepatitis C. 2012edition. Flying publisher, 2012;15 -20.
4. Sy T, Jamal MM. Epidemiology of Hepatitis C Virus (HCV) Infection. *International Journal of Medical Sciences* 2006;3(2):41-6.
5. Shepard CW, Finelli L, Fiore AE. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. *Pediatr Infect Dis J* 2005;24(9):755-60.
6. Frank C, Mohamed MK, Strickland GT. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000; 355(9207): 887-91.
7. Perz JF, Armstrong GL, Farrington LA. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006;45(4):529-38.
8. DeWolfe M and Laith J. Evidence of intense ongoing endemic transmission hepatitis C virus in Egypt. *PNAS* 2010;107(33): 14757–62.
9. Miriam J. Epidemiology of hepatitis c virus infection. *World J Gastroenterol* 2007; 13(17): 2436-41.
10. Alter M, Kruszon D, Nainan O. The prevalence of HCV infection in the United States, 1988 through 1994. *N Engl J Med* 1999;341(8): 556–62.
11. Pybus O, Drummond A, Nakano T. The epidemiology and iatrogenic transmission of hepatitis c virus in Egypt. *MolBiolEvol* 2003; 20 (3): 381-7.
12. Deuffic-Burban S, Mohamed MK, Larouze B. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. *J Hepatol* 2006; 44(3): 455-61.
13. Hagan H, Snyder N, Hough E. Case-reporting of acute hepatitis B and C among injection drug users. *J Urban Health* 2002;79(4):579-85.
14. Robotin MC, Copland J, Tallis G. Surveillance for newly acquired hepatitis C in Australia. *J GastroenterolHepatol* 2004;19(3):283-8.
15. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. *Arthritis Rheum* Oct 1999;42(10):2204-12.
16. Cacoub P, Renou C, Rosenthal E. The GERMIVIC Groupe. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. *Medicine (Baltimore)* Jan 2000;79(1):47-56.

17. Dervis E, Serez K. The prevalence of dermatologic manifestations related to chronic hepatitis C virus infection in a study from a single center in Turkey. *Acta Dermatovenerol Alp Panonica Adriat Sep* 2005;14(3):93-8.
18. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. *Hepatology* 2002;36(1):S65-73.
19. Pawlotsky JM. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? *Hepatology* 1998;27:1700-2.
20. Lavillette D. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. *J Virol* 2005;79:6023-34.
21. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. *J Hepatol.* 1999;30:956-61.
22. Lok AS. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. *Hepatology* 1993;18:497-502.
23. Thio CL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. *J Clin Microbiol.* 2000;38:575-7.
24. NIH Consensus Statement on Management of Hepatitis C: 2002. *NIH Consensus State Sci Statements* 2002;19:1-46.
25. Backmund M, Reimer J, Meyer K. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. *Clin Infect Dis* 2005;40(5):330-5.
26. Edlin BR, Kresina TF, Raymond DB. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. *Clin Infect Dis* 2005;40(5):276-85.
27. Stuart C, Ray R, Anthony C. Genetic Epidemiology of Hepatitis C Virus throughout Egypt. *The Journal of Infectious Diseases* 2000;182(3):698-707.
28. Weinbaum C, Iyerla R, centers for disease control and prevention. Prevention and control of infections with hepatitis viruses in correctional settings. *MMWR Recomm Rep* 2003; 52(1):1-36.
29. Busch MP, Glynn SA, Stramer SL. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. *Transfusion* 2005;45(2):254-64.
30. Nafeh MA, Medhat A, Shehata M. Hepatitis c in a community in upper egypt: cross-sectional survey. *Am. J. Trop. Med. Hyg.* 2000;63(5-6):236-41.
31. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. *Ann Intern Med* 2003;138(3):197-207.
32. Halfon P, Khiri H, Feryn JM. Prospective virological follow up of hepatitis C infection in a haemodialysis unit. *J Viral Hepat* 1998;5(2):115-21.
33. Fabrizi F, Martin P, Dixit V. Detection of de novo hepatitis C virus infection by polymerase chain in hemodialysis patients. *Am J Nephrol* 1999;19(3):383-8.

34. Zampieron A, Jayasekera H, Elseviers M. European study on epidemiology and the management of HCV in the haemodialysis population—Part 1:centre policy. *EDTNA ERCA J.* 2004;30(2):84-90.
35. Hladik W, Kataaha P, Mermin J. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. *Trop Med Int Health* 2006;11(6):951-4.
36. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. *Int J STD AIDS* 2004;15(1):7-16.
37. Roberts EA, Yeung L. Maternal -infant transmission of hepatitis C virus infection. *Hepatology* 2002; 36(5):106-13.
38. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. *Hepatology* 2002;36:1439-45.
39. Dammacco F, Sansonno D, Piccoli C. The cryoglobulins: an overview. *Eur J Clin Invest.* 2001;31:628–38.
40. Morra E. Cryoglobulinemia. *Hematology Am Soc Hematol Educ Program.* 2005:368–372.
41. Retamozo, C. Diaz-Lagares, X. Bosch, S. De Vita, and M. Ramos-Casals, “Life-threatening cryoglobulinemia,” in *Autoimmune Diseases: Acute and Complex Situations.* 2011: pp. 133–62.
42. Terrier, D. Saadoun, D. Sène, S. Scerra, L. Musset, and P. Cacoub, “Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients,” 2010; 59(12): 1709–15.
43. Ferri C, Mascia MT. Cryoglobulinemic vasculitis. *Curr Opin Rheumatol.* 2006; 18:54–63.
44. Ammendola A, Sampaolo S, Ambrosone L. Peripheral neuropathy in hepatitis-related mixed cryoglobulinemia: electrophysiologic follow-up study. *Muscle Nerve* 2005;31:382–5.
45. Boukhris S, Magy L, Senga-mokono U. Polyneuropathy with demyelinating features in mixed cryoglobulinemia with hepatitis C virus infection. *Eur J Neurol.* 2006;13:937–41.
46. Carbonari M, Caprini E, Tedesco T. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. *J Immunol* 2005;174:6532–9.
47. Morales JM, Kamar N, Rostaing L, Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. *Contrib Nephrol* 2012; 176:10.
48. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. *Kidney Int* 1998;54:650–71.
49. Roccatello D, Fornasieri A, Giachino O. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. *Am J Kidney Dis* 2007;49:69–82.

50. Sansonno, G. Lauletta, L. Nisi. "Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia," *Clinical and Experimental Immunology* 2003;133: 275–82.
51. Sansonno, A. Carbone, V. De Re, and F. Dammacco. Hepatitis C virus infection, cryoglobulinaemia, and beyond 2007; 46: 572–8.
52. Neumann AU, Lam NP, Dahari H. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- α therapy 1998; 282:103–7.
53. Zignego AL, Ferri C, Pileri SA, Caimi P, Bianchi FB, Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. *Dig Liver Dis* 2007;39:2-17.
54. Dammacco F, Sansonno D, Piccoli C. The cryoglobulins: an overview. *Eur J Clin Invest* 2001;31:628–38.
55. Ni J, Hembrador E, Di Bisceglie AM. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. *J Immunol*. 2003;170:3429–39.
56. Zignego AL, Ferri C, Giannelli F. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. *Ann Intern Med* 2002;137:571–80.
57. Moore PA, Belvedere O, Orr A. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator 1999;285:260–3.
58. Litinskiy MB, Nardelli B, Hilbert DM. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. *Nat Immunol* 2002;3:822–9.
59. Mackay F, Siervo F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. *Curr Dir Autoimmune*. 2005;8:243–65.
60. Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. *Trends Immunol* 2002;23:113–5.
61. Schiemann B, Gommerman JL, Vora K. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. *Science* 2001;293:2111–4.
62. O'Connor BP, Raman VS, Erickson LD. BCMA is essential for the survival of long-lived bone marrow plasma cells. *J Exp Med* 2004;199:91–8.
63. Do RK, Hatada E, Lee H. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. *J Exp Med* 2000;192:953–64.
64. De Re V, Caggiari L, Simula MP, Role of the HLA class II: HCV-related disorders. *Ann N Y Acad Sci* 2007;1107:308-18
65. Silvestri F, Sperotto A, Fanin R. Hepatitis c and lymphoma. *Curr Oncol Rep*. 2000; 2:172–175.

66. Sene D, Limal N, Ghillani Dalbin P, Saadoun D, Piette JC, Cacoub P, Hepatitis C virus-associated B-cell proliferation-the role of serum B lymphocyte stimulator (BLyS/BAFF). *Rheumatology (Oxford)* 2007;46:65-69.
67. Bianchetti G, Bonaccini C, Oliva R, Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. *J Virol* 2007;81:4564-71.
68. Ferri C, Sebastiani M, Giuggioli D. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. *Semin Arthritis Rheum* 2004;33:355-74.
69. Hermine O, Lefrère F, Bronowicki JP. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. *N Engl J Med* 2002;347:89-94.
70. Bosello S, Pers JO, Rochas C. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy 2007; 20 (1): 1-8.
71. Avery DT, Kalled SL, Ellyard JI. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. *J Clin Invest* 2003;112:286-297.
72. Lesley R, Xu Y, Kalled SL. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. *Immunity* 2004;20:441-53.
73. Thien M, Phan TG, Gardam S. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. *Immunity* 2004;20:785-98.
74. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. *Arthritis Rheum* 2001;44:1313-19.
75. Ittah M, Miceli-Richard C, Eric Gottenberg J. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. *Arthritis Res Ther* 2006;8:51.
76. Stohl W, Metyas S, Tan SM. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. *Arthritis Rheum* 2003;48:3475-86.
77. Tan SM, Xu D, Roschke V. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. *Arthritis Rheum* 2003;48:982-92.
78. Sene D, Ghillani-Dalbin P, Thibault V. Long-term course of mixed cryoglobulinemia in patients infected with hepatitis C virus. *J Rheumatol* 2004;31:2199-206.
79. Toubi E, Gordon S, Kessel A. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. *J Autoimmun* 2006;27:134-9.

80. Fabris M, Quartuccio L, Sacco S. B-lymphocyte stimulator (BLyS) upregulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. *Rheumatology (Oxford)* 2007;46:37–43.
81. Shu HB, Johnson H. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. *2000*; 97 (16): 9156–61.
82. Gross JA, Johnston J, Mudri S. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. *Nature* 2000; 404: 995–99 .
83. Nardelli B, Belvedere O, Roschke V. Synthesis and release of B-lymphocyte stimulator from myeloid cells. *Blood* 2001; 97: 198–204 .
84. Mackay F, Woodcock SA, Lawton P. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. *J Exp Med* 1999;190: 1697–1710.
85. Khare SD, Sarosi I, Xia XZ. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. *Proc Natl Acad Sci USA* 2000; 97:3370–5 .
86. Thompson JS, Schneider P, Kalled SL. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. *J Exp Med* 2000;192: 129–135 .
87. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. *J Exp Med* 2000;192: 953–64 .
88. Batten M, Groom J, Cachero TG. BAFF mediates survival of peripheral immature B lymphocytes. *J Exp Med* 2000;192: 1453–66 .
89. Gross JA, Dillon SR, Mudri S. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. *Immunity* 2001; 15:289–30.
90. Rennert P, Schneider P, Cachero TG. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. *J Exp Med* 2000;192: 1677–84.
91. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. *Arthritis Rheum* 2001;44: 1313–19.
92. Groom J, Kalled SL, Cutler AH. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. *J Clin Invest* 2002;109: 59–68.
93. Schneider S, Roessli D, Excoffier L. ARLEQUIN ver 2000: a software for population genetics data analysis.
94. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. *Curr Biol* 2000;10: 785–8.
95. Thibault-Espitia A, Foucher Y, Danger R, Migone T, Pallier A, Castagnet S. BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. *2012* ;12 (10): 2754–62.

96. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling 2007;18 (5): 263–75.
97. Tangye SG, Bryant VL, Cuss AK, Good KL, BAFF, APRIL and human B cell disorders 2007; 18 (5): 305–17.
98. Gragnani L, Fognani E, Piluso A, Zignego AL. Hepatitis C virus- related mixed cryoglobulinemia: is genetics to blame? *World J Gastroenterol* 2013;19(47): 8910–5.
99. Shahin AA, Zayed HS, Elshazly MS. Evaluation of the liver condition in chronic hepatitis C virus patients with and without vasculitis. *The Egyptian rheumatologist* 2014; 36(4): 187-93.
100. Donada C, Crucitti A, Donadon V, Tommasi L, Zanette G, Crovatto M. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. *J Viral Hepat*, 1998; (5):179–85.
101. KayaliZ VE, Buckwold B, Zimmerman WN, Schmidt C, Hepatitis Cryoglobulinemia, and cirrhosis: a meta-analysis. *Hepatology* 2002; (36): 978–85.
102. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. *GISC. Italian Group for the Study of Cryoglobulinaemias QJM* 1995;(88):115–26.
103. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC. Extrahepatic manifestations of chronic hepatitis C. *Multivirc Group. Multidepartment Virus C. Arthritis Rheum* 1999;(42): 2204–12.
104. Ferri C. Mixed cryoglobulinemia. *Orphanet J Rare Dis* 2008;(3): 25.
105. Saadoun D, Asselah T, Resche-Rigon M, Charlotte F, Bedossa P, Valla D. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. *Hepatology* 2006; (43): 1337–45.
106. Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. *Gut* 1999; (45): 122–8.
107. Angello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. *N Engl J Med* 1992; (327):1490-95.
108. Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. *Arthritis Rheum* 2011; (63): 1748–75
109. Saadoun D, Terrier B, Semoun O, Sene D, Maisonobe T, Musset L .Hepatitis C virus-associated polyarteritis nodosa. *Arthritis Care Res (Hoboken)* 2011;(63): 427–35.
110. Gragnani L, Piluso A, Giannini C, Caini P, Fognani E. Genetic Determinants in Hepatitis C Virus–Associated Mixed Cryoglobulinemia: Role of Polymorphic Variants of BAFF Promoter and Fc_γ Receptors. *Arthritis & rheumatism* 2011;63(5):1446-51.

111. Groom, J., Kalled, SL, Cutler, AH, Olson, C, Woodcock, SA, Schneider, et la. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. *The Journal of Clinical Investigation* 2002; 109: 59–68.
112. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K: Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in Primary Sjogren's syndrome. *J Clin Immunol* 2005; 25:189-201
113. Toubi E, Gordon S, Kessel A. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. *J Autoimmun* 2006;27:134–9.
114. Fabris M, Quartuccio L, Sacco S. B-lymphocyte stimulator (BLyS) upregulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. *Rheumatology (Oxford)* 2007;46:37–43.
115. Tarantino G, Marco VD, Petta A, Serum BLyS/BAFF predicts the outcome of acute hepatitis c virus infection. *J Viral Hepat* 2009;16(6):397-405.
116. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K: Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. *Genes Immun* 2002, 3:424-7.

المخلص العربي

الكريوجلوبولينيميا هي بلازما ايمونوجلوبولين التي تترسب عند إنخفاض درجة الحرارة. النوع الأول للكريوجلوبولين هو ايمونوجلوبولين أحادي النوع وكثيراً ما يأتي مصاحب لأمراض الدم. أما النوع الثاني والثالث فهما كريوجلوبولين مختلط يتكون من ايمونوجلوبولين ميم أحادي ومتعدد النوع بالترتيب.

تتميز الكريوجلوبولينيميا المختلطة بثلاث صفات أساسية البقع والإجهاد وإلتهاب المفاصل. وكثيراً ما تتأثر العديد من الأعضاء كالكلي والجهاز العصبي بالكريوجلوبولين.

ومن الممكن أيضاً أن تصاحب الكريوجلوبولينيميا المختلطة العدوي والأمراض العضوية الشاملة حتى أنه منذ عام ١٩٩٠ العديد من الدراسات أثبتت أن الإلتهاب الكبدي الوبائي سي قد يكون عامل أساسي لحدوث هذا المرض.

إن العلاقة بين الكريوجلوبولينيميا المختلطة وعدوي الإلتهاب الكبدي الوبائي سي أوضحت نظرات جديدة حول تفسير العلاقة بين العدوي الفيروسية وظاهرة المناعة الذاتية والإضطرابات الليمفاوية النشطة الانقسام.

في الحقيقة أن الفيروس يحث الخلايا بي الليمفاوية المتعددة علي الإنقسام والزيادة بصفة مزمنة التي تنتج عنها بعد ذلك الأحادية النوع.

إن المرضي اللذين لديهم أعراض الكريوجلوبولينيميا المتعددة المصاحبة للإلتهاب الكبدي الوبائي سي يكون الأساس في خطة علاجهم هو القضاء علي الفيروس نهائياً. وقد يكون العلاج بهذه الطريقة هو السبيل لتراجع التطور المرض للإضطرابات الليمفاوية النشطة الانقسام.

وفي دراساتنا المقدمة نكون قد أوضحنا أن التعدد الشكلي الجيني لباف بروموتر له علاقة قوية بالكريوجلوبولينيميا المتعددة المصاحبة للإلتهاب الكبدي الوبائي سي وبالتالي توضع العلاقة بين الأساس الجيني في مرضي الالتهاب الكبدي الوبائي سي والإضطرابات الليمفاوية النشطة الانقسام.

وبهذه المعلومات التي نتجت من خلال الأبحاث كان لها الأثر الكبير علي خطط العلاج من خلال إستخدام الأجسام المضادة لباف في العلاج وتستخدم هذه الأدوية بالفعل في علاج مرض الزئبة الحمراء وبمزيد من النتائج المشجعة قد يستخدم هذا الأسلوب من العلاج في علاج الكريو جلوبيولينيا المتعددة المصاحبة للإلتهاب الكبدي الوبائي سي بعد إجراء التجارب الملائمة.

ومن المعوقات التي تقابلنا في الأبحاث الجينية هو كمية العينة خصوصاً أثناء التعامل مع مرض نادر مثل الكريوجلوبيولينما المتعددة.

التعدد الشكلي الجيني لباف بروموتر لحالات الكريوجلوبيلنيميا
المصاحبة للإلتهاب الكبدي الوبائي سي

رسالة

مقدمة لكلية الطب - جامعة الإسكندرية
إيفاءً جزئياً لشروط - الحصول على درجة

الماجستير في الباثولوجيا الإكلينيكية
والكيمياءية

مقدمة

أمانى سعيد أحمد السيد صقر

بكالوريوس الطب والجراحة
جامعة الإسكندرية ٢٠٠٧

كلية الطب
جامعة الإسكندرية
٢٠١٥

المشرفون

و. منى وجدي عياد حلمي

أستاذ مساعد الباثولوجيا الإكلينيكية والكيميائية
كلية الطب - جامعة الإسكندرية

و. أماني أحمد البنا

أستاذ مساعد أمراض الباطنة
كلية الطب - جامعة الإسكندرية

المشرف المشارك

و. داليا عبد المعطي النيلي

مدرس الباثولوجيا الإكلينيكية والكيميائية
كلية الطب - جامعة الإسكندرية

وذلك لخبرتها في مجال الباثولوجيا الجزيئية